Paiwise Medical Showcases AI-Powered Nasopharyngeal Carcinoma Radiotherapy Target Delineation System at the First Global Artificial Intelligence Product Application Expo

VCBeat has learned that from May 10 to 12, 2018, under the guidance of relevant national ministries and commissions and the People's Government of Jiangsu Province, the inaugural "Global AI Product Application Expo" was grandly held at the Suzhou International Expo Center. Themed "Smart Experience, Intelligent Life," the event showcased cutting-edge technologies and products in the field of artificial intelligence from both domestic and international sources. As a leading international provider of top-tier medical AI technologies, Bosh Vision Medical exhibited its automatic delineation system for clinical target volumes in nasopharyngeal carcinoma radiotherapy, along with other key AI technologies and products.

Baishi Medical Makes Appearance at the “Global AI Product Application Expo”

Baishi Medical is the first third-party artificial intelligence company to embed its products into the Philips IntelliSpace Discovery (ISD) platform. All data for its ISD-embedded automatic delineation system for clinical target volumes in nasopharyngeal carcinoma radiotherapy were annotated by chief physicians from Sun Yat-sen University Cancer Center, creating the highest-quality dataset in the industry.

Unlike other AI companies’ radiotherapy products, which can only automatically delineate the Gross Tumor Volume (GTV), Baishi Medical’s automatic delineation system for radiotherapy clinical target volumes can also automatically delineate the Clinical Target Volume (CTV). CTV delineation is critical for controlling tumor recurrence and metastasis in radiotherapy, and it represents the most technically challenging and time-consuming aspect of target volume delineation.

Baishi Medical’s products can reduce contouring time from 3–4 hours to under one minute, while ensuring high precision in target volume delineation, thereby significantly improving the work efficiency of radiation oncologists.

In March 2018, Dr. Huang Haibin, former Director of Clinical Applications and Training Solutions for the Asia-Pacific region at Elekta, a world-leading radiotherapy equipment manufacturer, joined Bestray Medical as Director of Clinical Solutions and Vice President. Dr. Huang holds a master’s degree from Peking Union Medical College/Chinese Academy of Medical Sciences and a Ph.D. from the Cleveland Clinic in the United States. During his tenure as Director of Clinical Applications and Training Solutions for Elekta’s Asia-Pacific region, he was responsible for formulating the department’s development strategies and comprehensive solutions for clinical applications and training. With over a decade of experience in R&D and management of medical devices at large multinational corporations, Dr. Huang has extensive networks in the radiotherapy and medical imaging industries. His appointment will accelerate the iterative updates and commercial deployment of Bestray Medical’s radiotherapy products, further enhancing its competitive advantage in the field of medical AI.

Dr. Huang Haibin, Vice President of Baishi Medical, stated that radiotherapy is currently one of the three major modalities for comprehensive cancer treatment and represents the most cost-effective approach. By leveraging medical imaging and computer simulation technologies, modern radiotherapy was among the first clinical fields to adopt precision medicine, offering numerous opportunities for integration with artificial intelligence (AI). A key strategic focus for Baishi Medical is to deeply align with clinical needs and develop internationally leading AI-powered radiotherapy solutions.

Baishi Medical’s competitive advantage primarily stems from its premier interdisciplinary team spanning computer science and medicine. Founder Lu Yao previously served as a researcher at the University of Michigan Medical School and is currently a Professor at the School of Data Science and Computer Engineering, Sun Yat-sen University, where he also directs the Laboratory for Computational Medical Imaging. He is a key research member at the National Collaborative Innovation Center for Oncology and the Sun Yat-sen University Cancer Center, bringing over a decade of experience and product development in medical image analysis and artificial intelligence. Core team members hail from top-tier computer science and medical institutions, including the University of Michigan, Carnegie Mellon University, Friedrich-Alexander-Universität Erlangen-Nürnberg, the University of Southern California, Cleveland Clinic, Peking Union Medical College, Chinese Academy of Medical Sciences, Sun Yat-sen University, Zhejiang University, and Huazhong University of Science and Technology.

In addition to its globally leading radiotherapy target delineation system for nasopharyngeal carcinoma, Baishi Medical offers a comprehensive analysis and testing solution for all pulmonary diseases, as well as China’s leading breast cancer detection and diagnostic system, an AI-assisted diagnostic system for liver cancer, and an AI-powered pathological analysis system. This has established a multi-modal, multi-disease product portfolio that delivers practical, high-value solutions to radiology, pathology, and radiation oncology departments.